Loading...
Loading...
Agilent Technologies (NYSE: A) and Seoul National University
Hospital, one of Korea's top medical centers, today announced a
strategic collaboration for the development and verification of various
biomarkers for the development of drugs, including narcotics,
immune-suppressants and biomarkers.
“There are gaps in the medical industry that hamper the quality of care
we can provide to patients,” said Prof. Byung-Hee Oh, president and CEO,
Seoul National University Hospital. “One area we want to address is the
development of biomarkers for early detection and effective monitoring
of a range of diseases.”
“Our hospital is pleased to collaborate with Agilent, the premier test
and measurement company,
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in